At SpyBiotech, we have great respect for the National CMV Foundation and the incredible work they do to raise awareness of cytomegalovirus (#CMV). Their commitment to supporting families, educating the public, and advancing research has made a significant impact in the fight against this virus. We share their mission to protect vulnerable populations—newborns, individuals with weakened immune systems, and others—from the lifelong challenges of CMV. Together, we aim to make a meaningful difference in patient lives and improve public health. Learn more about their incredible work: https://lnkd.in/g3zSjZks
SpyBiotech
Biotechnology Research
Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide
About us
SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.
- Website
-
http://www.spybiotech.com
External link for SpyBiotech
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Oxford
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Vaccine Development
Locations
-
Primary
7600 Quorum
Oxford Business Park North
Oxford, OX4 2JZ, GB
-
One Broadway
14th floor
Cambridge, MA 02142, US
Employees at SpyBiotech
Updates
-
Our team had an incredible experience at this year’s J.P. Morgan Healthcare Conference in San Francisco. It was a privilege to meet with some of our investors and engage with colleagues across the #biotech industry. A special thank you to Oxford University Innovation for hosting such a fantastic investor event, and to everyone who took the time to connect and discuss our innovative vaccine platform. Stepping out of the lab to exchange ideas with fellow industry leaders is always inspiring. #VaccineTechnology #JPM25
-
Thank you Oxford University Innovation for hosting last night’s investor event at #JPM25. Our CEO Mark Leuchtenberger and President & CSO Sumi Biswas were excited to present our company outlook for 2025 and share updates on our latest clinical advancements in #CMV. It’s always a pleasure connecting with our colleagues at Oxford – thank you to everyone who attended.
We hosted our second Oxford University Innovation transatlantic healthcare gathering during #JPM2025 - we were delighted our Spinout company leadership, together with existing and potential new investors joined us. Special thanks to our speakers 🔊 featured in the photo below: Nicola Blackwood, Chris Mammen, Mark Bodmer, Mark Leuchtenberger, Sumi Biswas, Steven Griffen, Lance Baldo, Keri Hildick, PhD, Arjun Jayaswal, PhD, Margaret Duffy and Andrew Wells. A shout out to our Oxford spinouts at the JPM Healthcare conference - Beacon Therapeutics, Nucleome Therapeutics, SpyBiotech, OMass Therapeutics, Perspectum Ltd, Theolytics, Evox Therapeutics Ltd, Granza Bio (YC W24), Ground Truth Labs, Orbit Discovery, OrganOx, Oxford Brain Diagnostics Ltd, Oxford Nanopore Technologies, RQ Biotechnology Ltd. , OxSonics Therapeutics, T-Cypher Bio and Valink Therapeutics. A big thank you 🙏 to Womble Bond Dickinson (US) LLP and HGF Limited for supporting us and to the AIA San Francisco for hosting our event. Also many thanks to UK Department for Business and Trade and University of Oxford founder and alumni colleagues and Oxford Science Enterprises colleague @Katya Smirnyagina for joining us. And the OUI team Adam Workman, Benedicte Menn and Andrea Stewart in the US and the marketing team supporting Adele Davies and Louise Male tremendously from afar. #JPMHealthcare #Lifesciences #Healthcare #OUI #Innovation
-
Day 1 of the J.P. Morgan Healthcare Conference is in the books. Our CEO Mark Leuchtenberger, President and CSO Sumi Biswas, CMO Prakash Bhuyan and CFO Keith-Harrison Dewedoff have been busy engaging with healthcare leaders and investors discussing our novel vaccine platform. We’re looking forward to engaging with more of our colleagues and investors during the rest of this exciting #JPMWeek!
-
We’re very excited to attend the J.P. Morgan Healthcare Conference next week in San Francisco, CA. Our full team will be at #JPMWeek, engaged in meetings and catch-ups to discuss our novel vaccine platform technologies targeting infectious diseases, cancer and chronic diseases. #VaccineTechnology #JPM25 #CMV
-
We support ACI Alliance’s call for universal newborn #CMV screenings, which are critical to enabling early diagnosis, appropriate intervention, and ultimately better outcomes for patients. To read more about federal CMV legislation, click here: https://lnkd.in/dyy4nY7W
ACI Alliance Calls for Universal cCMV Screening As 1 in every 200 US newborns has cCMV and delayed identification precludes timely intervention, the ACI Alliance Board of Directors urged the development and publication of a comprehensive statement to support policy efforts for screening at the state and national levels and highlight the importance of medical intervention. Newborn testing for cCMV enables appropriate diagnosis and intervention by multidisciplinary teams to support newborns and their families. Read the full paper at https://lnkd.in/dyy4nY7W
-
Human cytomegalovirus (CMV) is a widespread virus, and most people are exposed to it at some point in their lives. While it’s often asymptomatic, CMV can have serious consequences for people with weakened immune systems, organ transplant recipients, and even newborns. We are dedicated to raising awareness about CMV and developing innovative vaccine solutions to combat it. By deepening our understanding of this virus, we aim to make a meaningful impact on global health. Find more information on our website at https://spybiotech.com/ #Vaccines #InfectiousDisease #CMV
-
In August we welcomed Dr. Prakash Bhuyan as our Chief Medical Officer. With over 20 years of expertise in infectious diseases, Prakash plays a key role in advancing our mission to develop innovative vaccine solutions for global health challenges. His extensive experience in clinical development strengthens our efforts as we advance our Phase I CMV vaccine trial. We’re thrilled to have him on board as we work to meet critical medical needs with our vaccine platform. Meet the rest of our leadership team: https://lnkd.in/eZCFTAvW #Leadership #Vaccines #InfectiousDisease #CMV
-
Our CEO Mark Leuchtenberger and CSO Sumi Biswas are attending the Jefferies Healthcare Conference in London this week! We’re excited for the opportunity to connect and discuss our innovative vaccine platform. Conversations like these are essential as we build partnerships and exchange ideas to tackle complex infectious diseases. #VaccineTechnology #InfectiousDisease #CMV #JefferiesHealthcare